Ann: Appendix 4E and Financial Report 31 December 2015, page-2

So I read through the financials and could spot nothing I didn't already know. One little detail that stuck its head out: Perseis is now officially an ex-parrot.

The other ann just summarises what's in the more detailed financials. Treagus is as always careful in his commentary and is just reiterating what we've heard previously. In short, this ann is a tick the box exercise and any genuinely new information will be released separately.

This next paragraph doesn't really say anything we don't already know, but it does say it explicitly so I thought worth a quote:

-----

In the year ended 31 December 2015, the Group used cash of $12.7 million in operating activities. Following the raising of $6.3 million in additional share capital in November 2015, the Group had cash balances at 31 December 2015 of $16.6 million. In 2016, the Group will continue to invest in research and development and use cash in operating activities. The Directors monitor the Group’s cash position and initiatives to ensure that adequate funding continues to be available for the Group to meet its business objectives. In January 2016 Neuren engaged Leerink Partners, a leading US investment banking firm specializing in healthcare, as its corporate adviser to assist the Directors in evaluating all future options available to the Group. Such options may include transactions that will provide additional share capital or revenue. The timing and terms of any such transactions are presently unknown, however the Directors have a view that a transaction will proceed successfully